PRC2 targeting, using EZH2 inhibitor, represents a potent therapeutic strategy in a subgroup of MM patients resulting in a significant induction of polycomb target genes, genes associated with DNA methylation, TP53, and RB1 target genes. This evidence concerns the gene TP53 and Miyoshi myopathy.